Saturday, January 27, 2007

Greenfuel Technologies Corporation and IGV Team Up to Accelerate the Commercialization of Recycling Greenhouse Gases into Biofuels

Leading Algae-Based Biotechnology Companies in USA and Germany Team Up to Accelerate the Commercialization of Recycling Greenhouse Gases into Biofuels

Greenfuel Technologies Corporation, a leader in the development of algae bioreactor technology for recycling CO2 in flue gases into clean, renewable biofuels, announced that it has signed a strategic alliance agreement with IGV, a private industrial research institute headquartered in Pottsdam, Germany. IGV is a pioneer in micro-algae research and production with more than 80 commercial technology deployments worldwide. The announcement was made today in Pottsdam at a special signing ceremony attended by several Brandenburg government ministers and other high-ranking German dignitaries of science, industry and politics.

Under the terms of the agreement, GreenFuel and IGV will share proprietary algae bioreactor technology in an effort to accelerate the commercialization of biofuel production from recycled carbon dioxide in power plant flue gas emissions. GreenFuel and IGV will also pursue commercial opportunities together in Europe. Once in commercial production, the GreenFuel Emissions-to-Biofuels™ process will allow power plants to significantly reduce carbon dioxide emissions, generate carbon credits, and produce clean, renewable biofuels.

Algae are unicellular plants and, like all plants, they divide and grow using the process known as photosynthesis. GreenFuel estimates that its Emissions-to-Biofuels™ process can absorb a significant percentage of a power plant’s CO2 emissions during the daytime. Unlike typical agricultural biofuel feedstocks, such as soybeans or corn which have a limited harvest window, algae multiply every hour and can be harvested every day. Algae can also be grown on poor quality land with non-potable water, so they don’t compete for land suitable for food crops. The carbon-enriched algae contain lipid oils and starches that can be converted into biodiesel and ethanol for transportation fuels. The residual protein can be used for animal feed and nutritional supplements. GreenFuel is currently involved in a number of Emissions-to-Biofuels™ pilot projects in the USA, Australia, Europe, and South Africa.

“We are extremely impressed with the knowledge, experience and professionalism of the entire IGV organization,” said Cary Bullock, CEO of GreenFuel Technologies Corporation. “We believe that IGV will be a valuable and strategic partner in our efforts to bring our Emissions-to-Biofuels™ algal bioreactor systems into full-scale commercial production at a number of locations around the world.”

About GreenFuel Technologies Corporation

With more than a dozen pending patents, GreenFuel Technologies Corporation is a recognized leader in the development of algae bioreactor systems that recycle carbon dioxide into clean renewable biofuels. GreenFuel Technologies Corporation is winner of both the “2006 Platts Global Energy Award for Energy Emission Project of the Year,” and the “2006 Frost & Sullivan Innovation of the Year Award – Biofuels.” Founded in 2001, the company is headquartered in Cambridge, Massachusetts. For more information, visit

Lixte Biotechnology to Obtain High-Quality Tissue and Blood Samples from German University

Lixte Biotechnology to Obtain High-Quality Tissue and Blood Samples from German University

Lixte Biotechnology Holdings, Inc. announced today that its wholly owned subsidiary, Lixte Biotechnology, Inc., entered into an agreement with the Institute of Pathology at the University of Regensburg in Germany to obtain a supply of high quality, accurately annotated tissue and blood samples for cancers other than brain cancers. This arrangement provides Lixte with appropriate clinical samples for which permission has been obtained to study any molecular feature of the tissue for commercial purposes.

Clinical samples will be obtained from patients who have given their signed informed consent by persons identified by the University of Regensburg, Germany. These are employees of the University who have approval by the University to seek such permission under a consent form approved by the University. The scope of use has been narrowed to the study of human cancers for the purpose of developing improved methods of diagnosis, estimation of prognosis, treatment and understanding causation of human cancers.

About Lixte Biotechnology Holdings, Inc.

Lixte was organized to capitalize on opportunities for the company to develop low cost, specific, and sensitive tests for the early detection of cancers to better estimate prognosis, to monitor treatment response, and to reveal targets for development of more effective treatments. Lixte is concentrating on discovering biomarkers for common cancers for which better diagnostic and therapeutic measures are needed. For each of these diseases a biomarker that would enable identification of the presence of cancer at a stage curable by surgery could possibly save thousands of lives annually. In addition, biomarkers specific to these diseases may also provide clues as to processes (biological pathways) that characterize specific cancer types and that may be vulnerable to drug treatment targeted to the activity of the biomarker.

The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this release represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update forward-looking statements.

A Five-Year Forecast Of The Biotechnology Industry In The United States

A Five-Year Forecast Of The Biotechnology Industry In The United States

Research and Markets has announced the addition of “Biotechnology in the United States” to their offering.

Our Biotechnology in the United States industry profile is an essential resource for top-level data and analysis covering the biotechnology industry. It includes detailed data on market size and segmentation, plus textual analysis of the key trends and competitive landscape, demographic information, and descriptions of the leading companies.

Scope of this title:

Contains an executive summary and data on value, volume and segmentation
Provides textual analysis of the industry’s prospects, competitive landscape and leading companies
Includes a five-year forecast of the industry
Supported by the key macroeconomic and demographic data affecting the market
Why you should buy this report
Spot future trends and developments
Inform your business decisions
Add weight to presentations and marketing materials
Save time carrying out entry-level research
Market Definition

The biotechnology market consists of the development, manufacturing and marketing of products based on advanced biotechnology research. The market value reflects revenues of companies within this industry from product sales, licensing fees, royalties and research funding. Any currency conversions used in the creation of this report have been calculated using constant 2004 annual average exchange rates.

For the purposes of this report, Europe consists of Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom, Bulgaria, Czech Republic, Hungary, Poland, Romania, Russia, Slovakia and the Ukraine.

Asia-Pacific consists of China, Hong Kong, India, Japan, Malaysia, Singapore, South Korea, Vietnam, Australia and New Zealand.

The global market is composed of Europe, Asia-Pacific, US, Canada, Turkey, Argentina, Brazil, Chile, Colombia, Mexico, Algeria, Egypt, Israel, UAE, Saudi Arabia and South Africa.

Topics Covered:

Market overview
Market value
Market segmentation
Competitive landscape
Leading companies
Market forecasts
Macroeconomic indicators
Companies Mentioned:

Amgen Inc.
Applied Biosystems
Biogen Idec, Inc.
Chiron Corporation
Genentech, Inc.
Biogen Idec, Inc.
MedImmune, Inc.

Tuesday, January 23, 2007

Calif. biotech firm relocates to Northern Colorado

Calif. biotech firm relocates to Northern Colorado - North ...
By chester645(chester645)
Calif. biotech firm relocates to Northern Colorado - North Colorado Business Report "FORT COLLINS - The problems surrounding being a miniscule fish in an enormous pond have brought Northern Colorado its newest biotechnology company. ...

Growers prepare for biotech beets

Growers prepare for biotech beets
Capital Press (subscription) - Salem,OR,USA TWIN FALLS, Idaho - Sugar beets will soon join corn and alfalfa in the lineup of Roundup Ready crops grown in Southern Idaho. ...

Collaborative Research Center (CRC)

Rice News
The Faculty & Staff Newspaper of Rice University
Volume 16, Number 19
January 11, 2006

Center of attention
Rice University began construction last month on the 477,000-gross-square-foot, 10-story Collaborative Research Center (CRC) at the corner of Main Street and University Boulevard. The new facility will enable researchers and physicians from the world's largest medical center to team up with Rice University scientists and engineers on bioscience and biotechnology research and complement one another's capabilities.

Biotechnology is the key to improvements in soybean varieties

Biotechnology is the key to improvements in soybean varieties High Plains Journal - Dodge City,KS,USA Biotechnology has already had an impact on soybean production with the introduction of Roundup resistant varieties in 1996. Timothy Conner, senior director ...

Options galore in biotech

Options galore in biotech
Malaysia Star - Petaling Jaya,Malaysia
ENCOMPASSING fields from medicine to agriculture, bio-information to marine studies, and even touching ethical, legal and safety issues, biotechnology ...

GenoSensor Expands Into Asian Markets

GenoSensor Expands Into Asian Markets January 2007

GenoSensor has furthered its presence into the biotech sector by launching its full line of GenoExplorerTM microRNA products into Japan and China through two recent distribution agreements. The first comes after a year of negotiations with Daiichi Pure Chemicals Co, Ltd, a division of Daiichi Pharmaceutical, the third largest pharmaceutical in Japan. The contract gives Daiichi Pure Chemicals sole distribution rights in the Japanese market for an undisclosed number of years. Daiichi's optimism for the GenoExplorerTM product line was revealed early by a full page advertisement in last month's Japanese edition of Nature magazine in anticipation of the deal. The first shipment of GenoExplorerTM microRNA kits has been received by Daiichi Pure Chemicals, and both parties are very excited that these products are now being offered in Japan.

The details of GenoSensor's second deal went through much more rapidly, as an agreement was reached early with Cold Spring Biotech Corp. in China. The arrangement will allow Cold Spring Biotech to be the exclusive distributor of GenoSensor's GenoExplorerTM products in mainland China, Hong Kong, and Taiwan. Cold Spring Biotech is also a major distributor of other genomic products from manufacturers such as gene-chip giant Affymetrix, making them ideally suited to distribute the GenoExplorerTM line.

Until recently, GenoSensor had focused its efforts on service based business, but increasing demand, recent distribution agreements in Europe, and now agreements with Daiichi in Japan and Cold Spring Biotech in China have shifted their focus to delivering product kits to end users, which allows the users to perform microRNA expression experiments in their own labs. Company President James Xia commented, "This is exactly what we wanted for GenoSensor, and following this type of model we will place our products into the hands of more researchers and pharmaceuticals across the globe, this is a big step for us."

About GenoSensor Corporation:

GenoSensor is a privately held biotechnology company aiming to improve lives by providing genomic research products and services worldwide for gene expression profiling and genotyping, biomarker discovery, target validation, therapeutic assessment, and other bioscience applications. Major products include microRNA profiling packages, as well as custom dna-arrays for gene expression and genotyping.
For more information please visit:

About Daiichi Pure Chemicals, Co., Ltd.:

Daiichi Pure Chemicals, Co., Ltd. headquartered in Tokyo, Japan, is a life science company having four business areas: diagnostics, research products, fine chemicals, and contract research. Diagnostics is its core business. Founded in 1947, during the chaotic postwar period, its missions are to provide the finest research reagents and to contribute to the development of Japan's science and technology.
For more information please visit:

About Cold Spring Biotech Corp.:

Cold Spring Biotech Corp. was established in October of 1984 in Taipei, Taiwan by a group of young professionals. T he company's focus areas include genomics, proteomics, bioinformatics, drug discovery, molecular and cell biology, and other life science fields. They have a h eadquarters and three branch offices located in Taiwan, and have an additional five branches in mainland China.
For more information please visit:

Illinois Biotechnology Industry Organization and iBIO Institute Make Notable Additions to Boards of Directors

Illinois Biotechnology Industry Organization and iBIO Institute Make Notable Additions to Boards of Directors
Well-Regarded Scientists, Entrepreneurs and Major Company Executives Bring Great Depth to Leadership Teams

The Illinois Biotechnology Industry Organization—better known as iBIO—and its educational arm, the iBIO Institute, today announced the election of new additions to both companies’ Boards of Directors. The new Board members, who include leading scientists, entrepreneurs, and executives of globally recognized corporations, add depth and prestige to an already-strong lineup of medical, agricultural, industrial and environmental biotech representation.

iBIO Institute Gains Corporate and Academic Expertise

The iBIO Institute named as Chairman of the Board Mark Booth, President of Takeda Pharmaceuticals North America, Inc., the US subsidiary of Takeda Pharmaceutical Company Limited, Japan’s largest pharmaceutical company. Prior to being named President, Booth was formerly an EVP at Takeda, and before that a SVP at Immunex and a Divisional Vice President at Abbott.

Also named to the iBIO Institute Board was Dr. Robert A. “Bob” Easter, Dean of the College of Agricultural, Consumer and Environmental Sciences (ACES) at the University of Illinois. Easter, who was formerly head of the Department of Animal Sciences at University of Illinois, has been a member of the University faculty since 1976 and is considered a leading expert on swine production.

“These are two superb additions to the iBIO Institute Board of Directors,” commented iBIO President & CEO David Miller. “Mark Booth was actively involved in making the BIO 2006 show a great success. Takeda Pharmaceuticals North America is one of the fastest growing pharmaceutical companies in the US and with its newly opened corporate campus in Deerfield has made a demonstrable commitment to the Chicago area and Illinois.”

Miller added, “We are equally excited about recruiting Bob Easter. He is a man of great vision, one who brings immense credibility and academic credentials to the Institute’s ag-bio efforts. Bob Easter has already asserted leadership of our ag-bio strategy work. And he leads one of the top agriculture schools in the world.”

iBIO Board Adds Representation from Startup and Global Biotech, Agriculture Firms

Joining iBIO’s Board are John Benske of Amgen, Gretchen Sue Johnson of KeraCure, Cedric Loiret-Bernal of NanoInk, Bill Moffitt of NanoSphere, John Pieper of Dupont-Pioneer, and Greg Webb of Archer Daniels Midland.

John Benske is Senior Manager, State Government Affairs at Amgen Inc. A veteran biotechnology-pharma state government affairs specialist, he oversees all of Amgen's state legislative and regulatory lobbying activities in an eight state region. Before joining Amgen, Benske held progressively responsible governmental affairs positions for the Pharmacy Society of Wisconsin, TAP Pharmaceuticals, and AstraZeneca. “John Benske for some time now has been one of the biggest contributors to our government affairs effort at iBIO,” commented Board and Executive Committee member Kris Coryell, PhD, Senior Director, Government Affairs and Public Policy at Pfizer. “And it’s great to have a company of Amgen’s stature represented on our Board.”

Gretchen Sue Johnson is a veteran biotechnology and medical device industry executive with more than 15 years experience in the tissue and wound repair industry. Johnson serves as the President and Chief Operating Officer of KeraCure, an emerging biotechnology company commercializing products for the Active Wound Healing Market. She previously served as top sales executive at BioSurface Technologies and as Vice President of Wound Repair at Genzyme Tissue Repair following Genzyme’s acquisition of BioSurface Technologies.

Cédric Loiret-Bernal, M.D. is Chief Executive Officer of NanoInk. Inc., an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life science and other industries. Loiret-Bernal was previously the Chief Executive Officer and co-founder of GeneProt Inc., an industrial-scale proteomics company for which he raised more than $150 million from institutional investors and corporate partners such as Novartis, Compaq (now HP) and Bruker. Prior to GeneProt, he was a Partner and senior investment analyst at Brinson Partners; he also held many other senior positions in corporate strategic planning for Abbott Laboratories, in marketing at Haemonetics and Porgès-Synthélabo.

William P. Moffitt is President and Chief Executive Officer of Nanosphere, Inc. which offers a unique and powerful chemistry that simplifies molecular testing in order to create new standards in discovery, medical care, and public safety. Prior to Nanosphere, Moffitt served as President and Chief Executive Officer of point-of-care diagnostics manufacturer i-STAT Corp. through its IPO in 1992, and its acquisition in 2003 by Abbott Laboratories for $480 million. From 1973 through 1989 Moffitt held increasingly responsible executive positions with Baxter Healthcare Corporation and American Hospital Supply Corporation.

iBIO Chairman Norbert Riedel, CVP and Chief Scientific Officer at Baxter International Inc., hailed the additions to the iBIO Board. “We are very proud that Bill Moffitt, Cedric Loiret-Bernal and Gretchen Sue Johnson, who rank among the region’s top entrepreneurs, are willing to contribute to iBIO’s success as members of our Board of Directors. iBIO is committed to helping enhance the environment for biotechnology startups in the Midwest, and engaging these proven leaders in our work will provide a huge boost to those efforts.”

John Pieper serves as Business Director, for DuPont- Pioneer Hi-Bred International’s Eastern Market. Based in Bloomington, Illinois, he is responsible for sales, marketing, technical services, product logistics and administrative support for the region which includes Illinois, Indiana, Ohio, Pennsylvania, Delaware, and Maryland. Prior to assuming his current position in July of 2006, Pieper held a number of progressively more responsible sales management positions with DuPont Pioneer starting in 1984. He also worked as sales manager at Carrico Implement Company, as a partner and farmer at Sioux View Farms, and in various engineering and marketing roles for Caterpillar Tractor Company.

Gregory W. Webb is Vice President, Public Affairs at Archer Daniels Midland, where he is responsible for relations with business and producer organizations. He joined ADM in 1986, working mostly in the oilseed processing business throughout North America, including soybean, canola, sunflower, flax and cotton. In July 2002, he was named the Company’s North American Trade Representative for Grain and Oilseeds.

“So much of what makes Illinois and the Midwest unique in the life sciences comes from our strong agricultural community, and ADM as well as Dupont-Pioneer are globally recognized firms pursuing critical applications for healthier foods, renewable energy, and environmentally superior industrial products,” commented iBIO President & CEO David Miller. “John Pieper and Greg Webb, two veteran executives with deep experience in this sector, will add substantial depth to our agricultural efforts.

Illinois Biotechnology Industry Organization

The Illinois Biotechnology Industry Organization, also known as iBIO, champions biotechnology in Chicago, Illinois, and the surrounding Midwest region. iBIO’s mission is to strengthen the leadership position of Illinois and the Midwest as a globally recognized life sciences center, a great place to do business, and a great place to start businesses involving advanced technologies. Doing so creates jobs, wealth, and excitement, and contributes to the well being of people worldwide through medical, agricultural, industrial, and environmental applications. To learn more about iBIO and its programs, visit iBIO is headquartered in Chicago.

iBIO’s Leadership Sponsors are Abbott, Astellas US, Baxter International, Takeda Pharmaceuticals North America, and TAP Pharmaceutical Products.

iBIO Institute

Based in Chicago Illinois, the iBIO Institute provides education, training and research to the life sciences community and general public. The Institute implements K-12 and community college education programs; training for new and experienced biotechnology workers and entrepreneurs; and outreach to minority and other underserved communities. The iBIO Institute is an IRS certified public charity, and was founded by the Illinois Biotechnology Industry Organization, which champions the life sciences in Illinois and surrounding Midwest. To learn more about the Institute and its objectives, visit

Biotech News
Arizona Biotechnology

Thursday, January 04, 2007

Court Affirms $7 Million in Damages for Innogenetics (Public, EBR:INNX) in Patent Infringement Suit Abbott Laboratories (Public, NYSE:ABT)

Court Affirms $7 Million in Damages for Innogenetics in Patent Infringement Suit

Judge Denies Abbott Laboratories' Requests for New Trial

GENT, Belgium and MADISON, Wis., Jan. 4

Biotechnology Company Innogenetics announced today that a U.S. District
Court judge for the Western District of Wisconsin affirmed a previously
awarded $7 million damage verdict against Abbott Laboratories for
infringing the company's HCV genotyping patent. In the same ruling the
judge rejected Abbott's requests for a new trial on infringement and
The January 3, 2007 order also granted Innogenetics' motion for
prejudgment interest on the damage award and set a January 11 evidentiary
hearing date to consider the company's request for a permanent injunction
against Abbott's sale of infringing products. The judge's opinion vacated
the jury's determination that Abbott willfully infringed Innogenetics'
patent, and declined to award enhanced damages or attorneys fees.
"By upholding the jury's award of damages, today's ruling sends a
message to companies large and small that mistakenly believe they can
misappropriate others' innovations without regard for the law," said Frank
Morich, CEO of Innogenetics.
This litigation began in September 2005 when Innogenetics sued Abbott
Laboratories alleging that Abbott was infringing the company's United
States patent covering a method of genotyping the Hepatitis C Virus (U.S.
Patent No. 5,846,704, "the '704 patent"). Major diagnostic companies such
as Bayer, Roche, and Third Wave Technologies have taken a license to this
key patent in the field of HCV genotyping. On September 1, 2006, a jury
returned a unanimous verdict for Innogenetics that the '704 patent was
valid in all respects. On September 8, 2006, the jury unanimously found
that Abbott's actions had been willful, and directed Abbott to pay
Innogenetics $7 million in damages related to the infringement to date.
Today's ruling was on post- trial motions filed by Abbott seeking a new
trial, and Innogenetics' motions seeking an injunction against Abbott as
well as enhanced damages and attorneys fees.
About Innogenetics
Innogenetics is an international biopharmaceutical company building
parallel businesses in the areas of specialty diagnostics and therapeutic
In 2005, total revenues (product sales, royalties, and license fees)
reached euro 48.6 million, with a profitable Specialty Diagnostics
Division. Its Diagnostics Division develops a large number of specialty
products covering three areas: infectious diseases (hepatitis C, hepatitis
B, and HIV), genetic testing (HLA tissue typing and cystic fibrosis), and
neurodegeneration (Alzheimer's disease). In its Therapeutics Division,
Innogenetics focuses on the development of therapeutic vaccines to address
unmet medical needs in the field of infectious diseases, with two compounds
now in clinical trials (hepatitis C in phase IIb and hepatitis B in phase
Founded in 1985, Innogenetics is listed on Euronext Brussels [Ticker:
INNX]. Innogenetics' headquarters are in Gent, Belgium, with sales
subsidiaries in France, Germany, Italy, Spain, Brazil, and the United
States. Innogenetics employs 525 people worldwide and has a market
capitalization of approximately euro 282 million.
For further information, please contact:
Filip Goossens
Investor Relations Manager
Phone + 32 9 329 1639
Fax + 32 9 245 7625
TVA BE 0427.550.660 RPR Gent

Jeremiah A. Hall
Feinstein Kean Healthcare
Phone 1 415 677 2720

Forward looking statement
This press release contains forward-looking statements that involve
risks and uncertainties, including but not limited to projections of future
revenues, operating income, and other risks. Prospective investors should
be aware that these statements are estimates, reflecting only the judgments
and projections of Innogenetics' management, and no undue reliance should
be placed on such forward-looking statements.

SOURCE Innogenetics

Cepheid (NASDAQ:CPHD) wins $14.9m contract from US CDC for rapid detector of bird flu virus

Cepheid wins $14.9m contract from US CDC for rapid detector of bird flu virus

Sunnyvale, Calif., USA. The United States Centers for Disease Control and Prevention (CDC) has awarded Cepheid (NASDAQ:CPHD) a $14.9 million contract to develop a rapid point-of-care diagnostic system to detect influenza viruses A and B, and the H5N1 virus (also called avian influenza or bird flu) in human respiratory specimens.

An initial allocation of $2.4 million for phases 1 and 2 of the five-phase program was made on 1st December. The proposed test will be developed over a 30-month period as part of a government program directed at pandemic preparedness. Cepheid will develop a fully automated, self-contained test that does not require the user to have technical or specialized training as a "CLIA waived" product for use on its GeneXpert system.

The objective of the program is to develop a rapid, highly accurate patient test utilizing Real-Time PCR on a broadly disseminated basis in virtually any setting.

"The contract will provide funding for the development of an integrated single module GeneXpert system and a test cartridge to detect influenza viruses A and B, and H5N1, thereby providing general clinical utility for seasonal flu diagnosis in addition to its application in an influenza pandemic. In the event of an avian influenza pandemic, rapid detection of the H5N1 virus and accurate differentiation of this agent from other common causes of respiratory illness will serve a critical role in diagnosis and subsequent treatment of avian influenza cases," said Cepheid Chief Medical and Technology Officer, David H. Persing, MD, Ph.D.

"The only proven test methods based on PCR detection of the viral genome, are technically complex and are typically confined to highly specialized central laboratories. Currently available PCR systems do not provide the rapid turnaround or on-demand, 24/7 availability that is necessary for real-time decisions to be made regarding antiviral therapy or patient management. The GeneXpert system is the ideal platform for bringing state-of-the-art molecular diagnostic technology to the frontlines of medical practice," continued Dr. Persing.

According to the World Health Organization, since 2003 there have been 258 human cases of Avian Influenza, with an overall mortality rate of over 50%. Apart from vaccination, the most effective means of controlling the spread of an influenza pandemic is early case recognition, followed by isolation and antiviral therapy.

Rapid antigen-based tests available today are insensitive and are not designed to specifically identify H5N1. Antiviral treatment is most effective at treating and preventing the spread of the virus when it is given before the peak onset of influenza viral syndrome. The new Xpert Influenza test under development will detect the common forms of human influenza virus (influenza A/B) as well as the H5N1 variant directly from nasal and throat swabs in approximately 30 minutes.

"The technology embedded in the GeneXpert platform constitutes precisely what developing nations like Indonesia need in combating threats like avian influenza. The ease, simplicity and relatively low cost of the diagnosis of H5N1 virus using this assay system will allow an expanded reach and reliability of surveillance to levels unimaginable with currently deployed diagnostic technologies," said J. Kevin Baird, Ph.D., Director, ALERTAsia Foundation, Jakarta, Indonesia, a collaborator in the contract that will provide samples for testing.

"ALERTAsia looks forward to working with our committed friends at Cepheid, the Eijkman Institute for Molecular Biology, the National Institute of Health Research and Development of the Republic of Indonesia, the U.S. Department of Health and Human Services, and the U.S. Centers for Disease Control and Prevention in making this bright vision a reality across the length of the Indonesian archipelago."

About the GeneXpert molecular diagnostic platform

The GeneXpert System is a closed, self-contained, fully-integrated and automated platform that represents a paradigm shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of false positive results due to contamination. The GeneXpert System is the only system to combine on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect and identify targeted nucleic acid sequences and deliver diagnostic answers from unprocessed samples in approximately 30 minutes, whereas manual testing methods comprising the same advanced technology require several hours to several days. Cepheid's Xpert GBS test recently received FDA clearance for use in CLIA "Moderate Complexity" laboratories, the first such designation for a PCR-based test. The modular design of the GeneXpert Platform allows it to be adapted to a variety of laboratory environments, ranging from high-volume testing in reference and hospital laboratories to use in physician offices and urgent care centers.

Caliper Life Sciences, Inc. (NASDAQ: CALP)

Caliper Life Sciences Closes Multiple LabChip and IVIS Sales at Top Pharma and Biotech Companies
Pfizer, AstraZeneca and Momenta Pharmaceuticals Purchase Caliper Systems for In Vitro and In Vivo Research Efforts

HOPKINTON, Mass., Dec. 12 Caliper Life Sciences, Inc. (NASDAQ: CALP) , today announced expanded sales of its LabChip(R) and IVIS(R) drug discovery and development systems to top-tier customers including Pfizer, AstraZeneca, and Momenta Pharmaceuticals. These systems help scientists accelerate and improve drug discovery and development.

Caliper's LabChip and IVIS systems connect research data from in vitro experimentation (outside a living organism) to in vivo experimentation (inside a living organism), while providing the highest precision, efficiency and quality of data. By connecting in vivo and in vitro experimentation, researchers are better able to predict human outcomes and reduce drug candidate attrition. Caliper's portfolio of offerings provides the pharmaceutical industry with the technology and support to improve clinical relevance and more rapidly develop effective treatments for disease.

"With the Caliper name supporting the IVIS imaging system, we are seeing rapid adoption in the commercial sector," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "The sales of both products are representative of Caliper's ability to meet the needs and demands of the industry while fostering the company's own growth and strategic direction as a leading provider of in vitro and in vivo drug discovery and development technologies."

About Caliper Life Sciences

Caliper Life Sciences is a leading provider of drug discovery and life sciences research solutions for the pharmaceutical and biotechnology industries. With its acquisitions of NovaScreen Biosciences and Xenogen Corporation, Caliper has positioned itself to transform drug discovery and development through a keen focus on clinically relevant experimentation. Caliper's products and services, assembled from a leading portfolio of microfluidics, liquid handling, and imaging technologies, span in vitro and in vivo experimentation and address key issues on the critical path of drug discovery and development. More information about Caliper can be found at .

NOTE: Caliper, Xenogen, IVIS and LabChip are registered trademarks of Caliper Life Sciences, Inc

Caliper Life Sciences' Presentation (NASDAQ: CALP)

Caliper Life Sciences' Presentation at JPMorgan 25th Annual Healthcare Conference to Be Webcast

HOPKINTON, Mass., Jan. 3 - Caliper Life Sciences, Inc. (NASDAQ: CALP) , today announced that its presentation at the JPMorgan 25th Annual Healthcare Conference will be webcast on Wednesday, January 10, 2007 at 4:00 p.m. PST. Kevin Hrusovsky, President and CEO of Caliper, will be presenting. The live webcast can be accessed at . An archived presentation will be available for 90 days.

About Caliper Life Sciences

Caliper Life Sciences is a leading provider of drug discovery and life sciences research solutions for the pharmaceutical and biotechnology industries. With its acquisitions of NovaScreen Biosciences and Xenogen Corporation, Caliper has positioned itself to transform drug discovery and development through a keen focus on clinically relevant experimentation. Caliper's products and services, assembled from a leading portfolio of microfluidics, liquid handling, and imaging technologies, span in vitro and in vivo experimentation and address key issues on the critical path of drug discovery and development.

Harvard Bioscience, Inc., HBIO President Announces Completion of Stock Transactions under 10b5-1 Plan

HBIO President Announces Completion of Stock Transactions under 10b5-1 Plan
Wednesday November 1, 10:44 am ET

HOLLISTON, Mass Harvard Bioscience, Inc., (Nasdaq: HBIO - News) today announced that its president, David Green, has completed the stock transactions under a stock-trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 which was adopted on March 14, 2006.

The plan was adopted during an authorized trading period at a time when Mr. Green was not in possession of material, non-public information.

About Harvard Bioscience

Harvard Bioscience (HBIO) is a global developer, manufacturer, and marketer of a broad range of specialized products, primarily scientific instruments and apparatus, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. HBIO sells its products to thousands of researchers in over 100 countries through its 1,100 page catalog (and various other specialty catalogs), its website and through its distributors, including GE Healthcare, Fisher Scientific and VWR. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, and Austria with additional facilities in France and Canada.

U.S. EPA fines Bio Rad Laboratories $29,900 for waste violations in Richmond, Calif.

U.S. EPA fines Bio Rad Laboratories $29,900 for waste violations in Richmond, Calif.

Release date: 12/13/2006

Contact Information: Dean Higuchi, 808-541-2711, Mark Merchant, 415-947-4297, merchant.mark@epa .gov

(12/13/06 -- SAN FRANCISCO) The U.S. Environmental Protection Agency recently settled with Bio Rad Laboratories, located in Richmond, Calif, for $29,900 for hazardous waste storage violations.

The EPA inspected the company’s facility in April 2005 and found the company was not complying with requirements to control air emissions from hazardous waste, a violation of the agency’s hazardous waste regulations.

Bio-Rad is a large quantity generator of hazardous waste and distributes over 200 life science research products, such as buffers, reagents, dyes, and ion exchange beads, for the biotechnology industry. The company is located at 3110 Regatta Blvd.

“We are pleased the company has taken responsibility for its violations and now understands what it needs to do in order to manage its hazardous waste,” said Jeff Scott, the EPA’s director for the waste management programs in the Pacific Southwest region. “All companies, generating hazardous waste must follow the rules to protect its employees, the public, and the environment.”

The company also failed to:

  determine what kind of hazardous waste was generated;
  properly train its workers in managing and handling hazardous waste;
  have a hazardous waste spill response plan; and
  store hazardous waste in required containers with proper labels.

The EPA’s hazardous waste rules require facilities to properly store, label and seal hazardous waste containers. Facilities must also have properly trained staff, as improperly stored hazardous waste can potentially spill and pose a risk to workers and the environment.

For more information on U.S. EPA’s hazardous waste program visit

Bio-Rad Launches Next Generation Antigen-based Kit

Bio-Rad Launches Next Generation Antigen-based Kit

Bio-Rad India, a 100 per cent subsidiary of Bio-Rad Laboratories USA, recently announced the launch of new ULTRA test kits for HIV and Hepatitis B & C virus for the first time in the Indian market. These kits have been developed by Bio-Rad in association with the renowned Pasteur Institute of France.

"Presently, it takes approximately 20-25 days for detection of antibody in HIV and approximately 45-60 days for HCV. This time period shall be reduced to 8-10 days by detecting both antigen and antibody for HIV and 4-10 days for HCV," said Dhiren Wagle, Country Manager for Bio-Rad India. He further added "Earlier detection by both antigen and antibody will reduce the window period and shall help doctors at blood banks be able to provide safer blood."

The HIV and Hepatitis test kits shall be marketed under the brand name of Genscreen HIV ULTRA Ag-Ab, HBsAg Ultra and Monolisa HCV ULTRA Ag-Ab respectively. The new generation kit is most advanced in its segment because of its antigen detection ability.

Biotech News - Arizona biotech industry ahead of 10-year schedule

Arizona biotech industry ahead of 10-year schedule

By Joe Pangburn, Inside Tucson Business
Posted: Friday, Dec 08, 2006 - 02:17:06 pm MST

Bioscience is taking root in the state, but how well it grows over the next six years will make all the difference in deciding whether Arizona will lead in the field, or just play follow-the-leader.

Speaking at the latest update of the 2002 Bioscience Roadmap, Walter Plosila, Battelle vice president, said the plan they wrote continues to point the way, and the state's government, industries and educational institutions are keeping on the path it established.

He said Arizona's biotechnology industry is meeting and exceeding expectations that were laid out four years ago in the Arizona Bioscience Roadmap, a 10-year plan to boost the state as a national competitor in the biosciences.

It was put together by the Battelle Technology Partnership Practice.

"Arizona is well on its way to achieving the 2007 midpoint goals set back in 2002," Plosila said.

More here

Yahoo! HotJobs

Find the right one

Search for jobs

across the web

Yahoo! News

Adventure Beat

Travel the world

with Richard Bangs

Yahoo! Groups

Start a group

in 3 easy steps.

Connect with others.



Amgen (AMGN) Amgen Gets a Boost

Amgen Gets a Boost

Amgen (AMGN - commentary - Cramer's Take - Rating) was advancing Thursday after two Wall Street research firms offered positive commentary on the biotech company's stock.

Bear Stearns upgraded Amgen to outperform from peer-perform, and Wachovia issued a report detailing five reasons to own the stock in 2007.

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY)

Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Docetaxel
Wednesday January 3, 8:30 am ET

CALGARY, Jan. 3 Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN® in combination with docetaxel (Taxotere®) in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal. The principal investigator is Professor Hardev Pandha of The Royal Surrey Hospital, U.K. Docetaxel is used in patients with lung, breast and prostate cancers, and is also used widely in the treatment of many other types of cancers.

"The trial is expected to yield data that will further characterize responses in these target patient populations and will help in designing the late-stage development program for REOLYSIN®," said Dr. Brad Thompson, President and CEO of Oncolytics.

In preclinical studies conducted at the U.S. National Cancer Institute (NCI) and Royal Surrey Hospital in the U.K., the combination of REOLYSIN® and various taxanes including docetaxel has been shown to be synergistic against a variety of cancer cell lines.

The trial (REO 010) has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN® given intravenously with docetaxel every three weeks. A standard dosage of docetaxel will be delivered with escalating dosages of REOLYSIN® intravenously. A maximum of three cohorts will be enrolled in the REOLYSIN® dose escalation portion. The second component of the trial will immediately follow and will include the enrolment of a further 12 patients at the maximum dosage of REOLYSIN® in combination with a standard dosage of docetaxel.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours such as bladder, lung, prostate or upper gastro-intestinal cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN® when administered in combination with docetaxel. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

In the U.K. and the U.S., approximately 600,000 people are diagnosed annually with bladder, lung, prostate and upper gastro-intestinal cancers.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN®, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit

For more information about docetaxel (taxotere®) please visit

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. combination REOLYSIN®/docetaxel clinical trial, and the Company's belief as to the potential of REOLYSIN® as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN® as a cancer treatment, the tolerability of REOLYSIN® outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN®, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.

Source: Oncolytics Biotech Inc.

Arizona biotech industry ahead of 10-year schedule

Arizona biotech industry ahead of 10-year schedule

By Joe Pangburn, Inside Tucson Business
Posted: Friday, Dec 08, 2006 - 02:17:06 pm MST

Bioscience is taking root in the state, but how well it grows over the next six years will make all the difference in deciding whether Arizona will lead in the field, or just play follow-the-leader.

Speaking at the latest update of the 2002 Bioscience Roadmap, Walter Plosila, Battelle vice president, said the plan they wrote continues to point the way, and the state’s government, industries and educational institutions are keeping on the path it established.

He said Arizona’s biotechnology industry is meeting and exceeding expectations that were laid out four years ago in the Arizona Bioscience Roadmap, a 10-year plan to boost the state as a national competitor in the biosciences.

It was put together by the Battelle Technology Partnership Practice.

“Arizona is well on its way to achieving the 2007 midpoint goals set back in 2002,” Plosila said.

More here: